31 October 2019

Radboud university medical center and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.
  
“Radboudumc strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboudumc. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”
 
Person-oriented treatment
The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”
 
Image-guided treatment
Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."
 
Working together on innovative applications
Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”


About Quirem Medical
Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.

 

Related news items


Three Vici grants for Radboudumc researchers

20 February 2020

Christian Beckmann, Sander Leeuwenburgh and Annette Schenck each receive a 1.5 million euro Vici research grant from NWO.

read more

Dutch Brain Foundation grant for EENnacoma

20 February 2020

Lavrijsen and Van Erp: ‘This grant will facilitate practice-based research, professionalization and further academization of EENnacoma, and links between different health care and research institutions all for the benefit of people with prolonged disorders of consciousness and their families.'

read more

RIHS Awards Ceremony five winners

19 February 2020

On 18 February the RIHS 'Koek & Zopie' event took place. In front of an audience of more than 125 colleagues, RIHS awardees accepted their awards for the best PhD thesis, the research product with the highest impact on society, the best peer-reviewed publication and the Supervisor of the year 2019.

read more

Preserved specific force in facioscapulohumeral muscular dystrophy

19 February 2020

DCMN researcher Saskia Lassche et al., theme Disorders of Movement, recently showed in Neurology that remaining muscle fibers in Facioscapulohumeral muscular dystrophy (FSHD) patients  have normal muscle strength, even in severely affected muscles.

read more

Researchers investigate how stem cells affect the immune system

18 February 2020

RIMLS researchers Irma Joosten and Renate van der Molen, participating in an European study into the treatment of brain damage in premature babies. Is it possible to limit or even partly repair the damage with stem cells? They focus primarily on the effect of those stem cells on the immune system.

read more

Lowlands Science call for projects

17 February 2020

Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.

read more